vTv Therapeutics Inc(VTVT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.06 | Insider Own | 47.93% | Shs Outstand | 3.9M | Perf Week | -1.49% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | -243.31% | Insider Trans | - | Shs Float | 2.1M | Perf Month | -20.97% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -1.09 | Inst Own | 30.86% | Short Float | 6.96% | Perf Quarter | -22.29% |
| Income | -0.00B | P/S | 2.7 | EPS this Y | 62.25% | Inst Trans | 9.83% | Short Ratio | 2.89 | Perf Half Y | -20.56% |
| Sales | 0.04B | P/B | 1.26 | EPS next 5Y | -12.78% | ROA | -8.34% | Short Interest | 0.14M | Perf YTD | -37.06% |
| Book/sh | 19.96 | P/C | 1.15 | EPS past 3/5Y | 32.12% 14.99% | ROE | -11.69% | 52W High | -42.8% ($44.00) | Perf Year | 19.46% |
| Cash/sh | 21.91 | P/FCF | - | Sales past 3/5Y | - | ROIC | -6.05% | 52W Low | 25.6% ($20.04) | Perf 3Y | 44.96% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 75.57% | Gross Margin | 99.98% | Volatility(W/M) | 4.78% 5.12% | Perf 5Y | -56% |
| Dividend TTM | - | EV/Sales | 0.35 | Sales Y/Y TTM | 216600% | Oper. Margin | -25.11% | ATR (14) | 1.4 | Perf 10Y | -88.72% |
| Dividend Ex-Date | - | Quick Ratio | 12.48 | EPS Q/Q | -14.61% | Profit Margin | -12.91% | RSI (14) | 32.85 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.48 | Sales Q/Q | - | SMA20 | -9.63% ($27.85) | Beta | 0.25 | Target Price | $57.38 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/6 | SMA50 | -16.88% ($30.28) | Rel Volume | 0.29 | Prev Close | $26.38 |
| Employees | 26 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -8.25% -100% | SMA200 | -24.88% ($33.51) | Avg Volume(3M) | 0.05M | Price | $25.17 |
| IPO | 2015/7/30 | Option/Short | No/Yes | Trades | 472 | Volume | 14,218 | Change | -4.59% |
🧬 vTv Therapeutics (VTVT) is a US-based clinical-stage biopharmaceutical company focused on developing oral small-molecule drug candidates in metabolic disease areas, including diabetes. As a pipeline-driven R&D company whose commercial revenue has yet to scale meaningfully, clinical progress is the core driver of its corporate value.
Over the past 1 year, on the lower side
43% below its 1-year high.
Traded less than usual. That is 29% of its average volume.
VTVT has a sound balance sheet but weak earning power
Of every $100 in sales, $25.11 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +62.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $270. Peers typically go for $1,010.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -56.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 30.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #355 of 597 in the industry
Based on market cap of $100M.
VTVT#355 vTv Therapeutics Inc $100M PER - 
PMVP#356 PMV Pharmaceuticals Inc $99M PER - 
CBUS#357 Cibus Inc $99M PER - 
VANI#358 Vivani Medical Inc $98M PER - 
NRXP#359 NRX Pharmaceuticals Inc $98M PER - 
FAQ
What kind of company is VTVT?
VTVT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VTVT?
The market cap of VTVT is approximately $100M, ranking 4,461 within its sector.
What is the 52-week high and low for VTVT?
VTVT has recorded a 52-week high of $44.00 and a low of $20.04.
